SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) On April 7, 2021 Oncology Pharma, Inc. (the "Company") reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments utilizing Regen's proprietary intellectual property pertaining to mRNA.
A Spokesperson for the Company, today expanded on the reasons for obtaining this license stating:
"Pancreatic Cancer is one of the most lethal forms of cancer ranking as the fourth leading cause of cancer deaths in the United States. The median survival duration from diagnosis until death for untreated advanced pancreatic cancer is approximately 3 1/2 months; increasing to about eight months with treatment.
mRNA vaccines have become a promising platform for cancer immunotherapy. The intellectual property which we licensed from Regen encompasses an exciting method of utilizing mRNA to cause changes in the cancer cells which would stimulate the patient's own immune response to battle this deadly disease.
According to the National Cancer Institute more than 1.7 million new cases of pancreatic cancer emerge in the United States per year resulting in 609,604 deaths. The cost of treating pancreatic cancer in the United States is $174 billion per year and growing. These are staggering numbers.
We believe that developing a solid therapy to treat this disease is our mission. We want to help save lives and bring hope where currently little hope exists. We believe our mRNA based pancreatic cancer therapies will prove dynamic and powerful."
The Spokesperson further noted "We are more than a biotechnology company. We believe our shareholders expect us to not only develop therapies that improve lives but to develop therapies that save lives. Knowing what we know about pancreatic cancer, this is a great cornerstone on which to focus our Company's research activities."
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: [email protected]
SOURCE: Oncology Pharma Inc.